TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30375109

Group type: EXPERIMENTAL
Intervention: Higher dose: paracetamol 15 mg/kg + ibuprofen 4.5 mg/kg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Lower dose: paracetamol 12 mg/kg + ibuprofen 3.6 mg/kg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Both doses of the fixed-dose combination
Number of subjects: 251
Study: 26571159

Group type: EXPERIMENTAL
Intervention: Contralateral slump test (ST)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (ST)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 61
Study: 24752957

Group type: EXPERIMENTAL
Intervention: Levofloxacin (10 mg/kg, maximum 500 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rifampicin (10 mg/kg, maximum 450 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levofloxacin and Rifampicin
Number of subjects: 120
Study: 22905454

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20663795

Group type: EXPERIMENTAL
Intervention: GnRH analogues
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 17610348

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both Metformin and Simvastatin
Number of subjects: 41
Study: 16282000

Group type: EXPERIMENTAL
Intervention: Active treatment (pharmacological or psychological)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Higher symptom score (measured by GHQ)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Anxiety disorder
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Chronic mixed anxiety/depression
Number of subjects: 439
Study: 12849425

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drugs (including glucocorticoid therapy, hydroxychloroquine, NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucocorticoid therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0
Study: 10200132

Group type: EXPERIMENTAL
Intervention: Salmeterol (200 micrograms daily, b.i.d. for 3 weeks)
Number of subjects: 17
Study: 7779545

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (G1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Coronary artery disease without MI history (G2)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy volunteers (G3 and G4)
Number of subjects: 84
Study: 2099245

Group type: EXPERIMENTAL
Intervention: Home monitoring of blood pressure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hospital monitoring of blood pressure
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Circadian rhythm analysis of systolic BP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Circadian rhythm analysis of diastolic BP
Number of subjects: 15
Study: 6117726

Group type: EXPERIMENTAL
Intervention: Ribavirin small-particle aerosol treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 31
Study: 31747001

Group type: EXPERIMENTAL
Intervention: Workers who perceived work-relatedness (WR+)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Workers who did not perceive work-relatedness (WR-)
Number of subjects: 209
Study: 30744452

Group type: EXPERIMENTAL
Intervention: Intensive treatment arm (target DBP <70 mm Hg)
Number of subjects: 8944

Group type: COMPARATOR
Intervention: Standard treatment group (target DBP ≥70 mm Hg)
Number of subjects: 8944
Study: 27932608

Group type: EXPERIMENTAL
Intervention: Pocapavir (n = 93)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (n = 48)
Number of subjects: 144
Study: 25331699

Group type: EXPERIMENTAL
Intervention: 2% LTX-109
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5% LTX-109
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 100
Study: 23899131

Group type: EXPERIMENTAL
Intervention: Cold compress
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (3% solution)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Over-the-counter bruise serum
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 17
Study: 21504885

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 20002471

Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase (ALT)
Number of subjects: 41111

Group type: COMPARATOR
Intervention: Geographic regions (Asia vs others)
Number of subjects: 41111
Study: 17223803

Group type: EXPERIMENTAL
Intervention: Inflation with air via a facepiece attached to a self‐inflating bag
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard procedure without inflation
Number of subjects: 160
Study: 15370406

Group type: EXPERIMENTAL
Intervention: 0.05% retinaldehyde with non-ablative laser (1540 nm Er:glass, 10 J/cm2 per pulse, three pulses, 2 Hz repetition rate, 4 mm spot, +5 degrees C cooling)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Excipient with non-ablative laser (1540 nm Er:glass, 10 J/cm2 per pulse, three pulses, 2 Hz repetition rate, 4 mm spot, +5 degrees C cooling)
Number of subjects: 16
Study: 11474633

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg once daily)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Trovafloxacin (200 mg once daily)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 571

Group type: COMPARATOR
Intervention: Trovafloxacin
Number of subjects: 571
Study: 9740930

Group type: EXPERIMENTAL
Intervention: 150 micrograms clonidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 100 micrograms clonidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 75 micrograms clonidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 75, 100 and 150 micrograms clonidine
Number of subjects: 60
Study: 8311309

Group type: EXPERIMENTAL
Intervention: Combined epidural/enflurane anesthesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Enflurane alone
Number of subjects: 26
Study: 3171225

Group type: EXPERIMENTAL
Intervention: Ceftriaxone iv in single daily doses of 75 mg/kg for children and 3-4 g for adults for seven days
Number of subjects: 63

Group type: COMPARATOR
Intervention: Chloramphenicol 60 mg/kg a day orally or iv in four divided doses until defervescence and then 40 mg/kg a day to complete 14 days
Number of subjects: 63
Study: 31726935

Group type: EXPERIMENTAL
Intervention: Viewing images of infants
Number of subjects: 101

Group type: COMPARATOR
Intervention: Viewing images of adults
Number of subjects: 101
Study: 30347104

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (Sellick group)
Number of subjects: 3472

Group type: COMPARATOR
Intervention: Sham procedure group
Number of subjects: 3472
Study: 28419027

Group type: EXPERIMENTAL
Intervention: Positive-belief treatment (inert capsule described as a potent supplement)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Negative-belief treatment (inert capsule described as a potent supplement)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Control treatment (received neither instruction nor capsule)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Intention to use supplements (within positive-belief treatment)
Number of subjects: 627
Study: 26514221

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (2 g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraarticular tranexamic acid (2 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 60
Study: 23306586

Group type: EXPERIMENTAL
Intervention: Higher intensity (HI) continuous renal replacement therapy (CRRT)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Lower intensity (LI) continuous renal replacement therapy (CRRT)
Number of subjects: 115
Study: 21680125

Group type: EXPERIMENTAL
Intervention: CT fluoroscopy (CTF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electromagnetic navigation system (EMN)
Number of subjects: 60
Study: 18084791

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 0
Study: 16406123

Group type: EXPERIMENTAL
Intervention: Encouraged to drink 240 ml of clear liquid prior to discharge
Number of subjects: 93

Group type: COMPARATOR
Intervention: Voluntary drinking of liquids
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups (encouraged and voluntary)
Number of subjects: 93
Study: 12875940

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Deferred hormonal treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: Immediate hormonal treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Immediate vs Deferred hormonal treatment
Number of subjects: 91
Study: 12751395

Group type: EXPERIMENTAL
Intervention: Isotonic sodium chloride solution (0.5 to 2.0 mL depending on age) during suctioning
Number of subjects: 24

Group type: COMPARATOR
Intervention: No isotonic sodium chloride solution during suctioning
Number of subjects: 24
Study: 10195518

Group type: EXPERIMENTAL
Intervention: 1% lidocaine (0.1 mL/kg) with 1:200,000 epinephrine (0.5 microg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: saline
Number of subjects: 32
Study: 7624902

Group type: EXPERIMENTAL
Intervention: Oral hydrochlorothiazide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral furosemide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous furosemide
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 10
Study: 2507548

Group type: EXPERIMENTAL
Intervention: Intravenous supplementation of enteral calories, n = 16
Number of subjects: 39

Group type: COMPARATOR
Intervention: Enteral calories alone, n = 23
Number of subjects: 39
Study: 892120

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide suspension
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Kromayer lamp (contact irradiation with ultraviolet light)
Number of subjects: 12
Study: 30623683

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Conventional exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 30663175

Group type: EXPERIMENTAL
Intervention: Acotiamide (100 mg tid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27993649

Group type: EXPERIMENTAL
Intervention: Monetary incentive feedback
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-monetary feedback
Number of subjects: 2
Study: 26394822

Group type: EXPERIMENTAL
Intervention: ADHD stimulant medication
Number of subjects: 8420

Group type: COMPARATOR
Intervention: No ADHD stimulant medication
Number of subjects: 8420
Study: 23712475

Group type: EXPERIMENTAL
Intervention: Surgical intervention (anterior cervical decompression and fixation) followed by anti-tuberculous medications (16 patients)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conservative management (anti-tuberculous medications only) (13 patients)
Number of subjects: 29
Study: 22000478

Group type: EXPERIMENTAL
Intervention: DHA (10mg/kg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 19544166

Group type: EXPERIMENTAL
Intervention: montelukast + loratadine
Number of subjects: 406

Group type: COMPARATOR
Intervention: beclomethasone
Number of subjects: 406

Group type: COMPARATOR
Intervention: montelukast
Number of subjects: 406
Study: 18001247

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 82
Study: 15551197

Group type: EXPERIMENTAL
Intervention: Paroxetine (PAROX) and Amitriptyline (AMI) in OPEN condition
Number of subjects: 127

Group type: COMPARATOR
Intervention: Blind-randomized treatment with Paroxetine (PAROX) and Amitriptyline (AMI)
Number of subjects: 127
Study: 11682575

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol x kg(‐1) x min(‐1) from 30 to 180 minutes)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (glucose and insulin alone infusion)
Number of subjects: 8
Study: 9502624

Group type: EXPERIMENTAL
Intervention: Saruplase (20-mg bolus and 60-mg infusion over 60 min)
Number of subjects: 3089

Group type: COMPARATOR
Intervention: Streptokinase (1.5-MU infusion over 60 min)
Number of subjects: 3089

Group type: EXPERIMENTAL
Intervention: Saruplase
Number of subjects: 3089

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 3089

Group type: EXPERIMENTAL
Intervention: Saruplase and Streptokinase
Number of subjects: 3089
Study: 8044938

Group type: EXPERIMENTAL
Intervention: Glibenclamide (10 mg oral)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 20
Study: 2904568

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (CBS) with placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) with tinidazole
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cimetidine with tinidazole
Number of subjects: 100
Study: 30208243

Group type: EXPERIMENTAL
Intervention: Ultrasound simulator training (2 self‐directed practice ultrasound sessions over 4 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no additional access to a simulator or ultrasound training)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Postintervention practical examinations
Number of subjects: 19
Study: 28219690

Group type: EXPERIMENTAL
Intervention: 3-year surveillance interval
Number of subjects: 1560

Group type: COMPARATOR
Intervention: 5-year surveillance interval
Number of subjects: 1560
Study: 25889313

Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) 0.3 mg/day for 3 days
Number of subjects: 97

Group type: COMPARATOR
Intervention: Scopolamine butylbromide (SB) 60 mg/day for 3 days
Number of subjects: 97
Study: 24063214

Group type: EXPERIMENTAL
Intervention: Routine acupuncture combined speech training (Group B)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Acupuncture combined language training (Group C)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Speech training (Group A)
Number of subjects: 132
Study: 21859820

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 803

Group type: COMPARATOR
Intervention: FOLFOX or FOLFIRI
Number of subjects: 803
Study: 19093729

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid (ALA) 600 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (C(NAC))
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (C(ALA))
Number of subjects: 28
Study: 18020969

Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation (2.5 mg folate, 0.5 mg vitamin B(12), 25 mg vitamin B(6))
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation in hyperhomocysteinemic subjects (HCY>15 mumol/L, n=8)
Number of subjects: 47
Study: 15472638

Group type: EXPERIMENTAL
Intervention: Adenosine stress in patients with extensive reversible perfusion defects (summed difference score > or =8)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no known CAD and normal LV perfusion and function)
Number of subjects: 86
Study: 11553204

Group type: EXPERIMENTAL
Intervention: Type 1 DM
Number of subjects: 6

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 6
Study: 9466103

Group type: EXPERIMENTAL
Intervention: Tramadol 20 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 7929979

Group type: EXPERIMENTAL
Intervention: long-bar overdenture
Number of subjects: 145

Group type: COMPARATOR
Intervention: fixed prosthesis
Number of subjects: 145
Study: 2460118

Group type: EXPERIMENTAL
Intervention: Digoxin (plasma drug concentration 1.3 to 2.0 nmol l‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diltiazem 120 mg three times daily
Number of subjects: 8
Study: 30702006

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual Care Control
Number of subjects: 158
Study: 29069260

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 60

Group type: COMPARATOR
Intervention: Air entrainment mask
Number of subjects: 60
Study: 25256283

Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 61

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 61
Study: 22864946

Group type: EXPERIMENTAL
Intervention: 5 mg D-amphetamine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 10 mg D-amphetamine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21471971

Group type: EXPERIMENTAL
Intervention: Amlodipine complex (5 mg amlodipine and 25 mg hydrochlorothiazide) administered at bedtime (2200 hours)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amlodipine complex (5 mg amlodipine and 25 mg hydrochlorothiazide) administered in the morning (0800 hours)
Number of subjects: 80
Study: 17428399

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy for house dust mite
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy for pollen
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (pharmacotherapy)
Number of subjects: 107
Study: 15820070

Group type: EXPERIMENTAL
Intervention: ProMACE‐CytaBOM regimen
Number of subjects: 146

Group type: COMPARATOR
Intervention: CHOP regimen
Number of subjects: 146
Study: 12466700

Group type: EXPERIMENTAL
Intervention: Bilateral ITA
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Single ITA
Number of subjects: 1069
Study: 9764882

Group type: EXPERIMENTAL
Intervention: Breastfeeding for > or = 7 months
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: High protein intake (i.e. > or = 16 energy percentage)
Number of subjects: 339
Study: 8562150

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 200
Study: 2669444

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 22
Study: 1194910

Group type: EXPERIMENTAL
Intervention: Nonpsychotic hospitalized schizophrenics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospitalized nonschizophrenics
Number of subjects: 0
Study: 30269322

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin combined with synchronous radiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct operation
Number of subjects: 40
Study: 26994516

Group type: EXPERIMENTAL
Intervention: Sarolaner (Simparica™) administered at a minimum dosage of 2.0 mg/kg (range 2-4 mg/kg) on Days 0, 30, and 60
Number of subjects: 466

Group type: COMPARATOR
Intervention: Spinosad (Comfortis® Chewable Tablets) as positive control
Number of subjects: 466

Group type: COMPARATOR
Intervention: Fipronil (Frontline® Spot on) as positive control
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Sarolaner (Simparica™) administered at a minimum dosage of 2.0 mg/kg (range 2-4 mg/kg)
Number of subjects: 466
Study: 24829414

Group type: EXPERIMENTAL
Intervention: SLE serum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to allogeneic T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN and SLE serum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TLR agonists (such as LPS)
Number of subjects: 0
Study: 22323625

Group type: EXPERIMENTAL
Intervention: Ballistic finger abduction training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Visuomotor tracking training
Number of subjects: 14
Study: 20221707

Group type: EXPERIMENTAL
Intervention: Iomeron 400 (400 mg I/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Iopamidol 300 (300 mg I/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study: 18556560

Group type: EXPERIMENTAL
Intervention: Updating training for 5 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Updating training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 0
Study: 15972319

Group type: EXPERIMENTAL
Intervention: 3.86% glucose
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1.36% glucose
Number of subjects: 8

Group type: COMPARATOR
Intervention: 7.5% icodextrin
Number of subjects: 8
Study: 12837192

Group type: EXPERIMENTAL
Intervention: Improved percutaneous tracheostomy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Old technique of percutaneous tracheostomy
Number of subjects: 107
Study: 11026855

Group type: EXPERIMENTAL
Intervention: Digital Subtraction Angiography (DSA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bolus Chasing Angiography (BCA)
Number of subjects: 75
Study: 8795677

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5
Study: 1374724

Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-fluorouracil (5-FU) administered as adjuvant treatment following liver resection (7 patients)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-fluorouracil (5-FU) administered as palliative chemotherapy (13 patients)
Number of subjects: 25
Study: 6375873

Group type: EXPERIMENTAL
Intervention: Effervescent metoclopramide and aspirin (Migravess) 650 mg and 10 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Effervescent aspirin 650 mg (Alka-Seltzer)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Effervescent metoclopramide and aspirin (Migravess)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Effervescent metoclopramide and aspirin (Migravess) vs Effervescent aspirin
Number of subjects: 118